Search research articles
Contact Us
Filters
Showing results (111-120 of 159) with videos related to
Page
of 16
Sort By:
Journal of Clinical Pharmacology
|
May 16, 2024
Exposure-Response Analyses for Belzutifan to Inform Dosing Considerations and Labeling
Dhananjay D Marathe, Petra M Jauslin, Huub Jan Kleijn, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
January 21, 2017
Challenges and opportunities in primary CNS lymphoma: A systematic review
Mariana N Kerbauy, Fabio Y Moraes, Benjamin H Lok, et al.
The Journal of Biological Chemistry
|
November 23, 2000
A 7-kDa prion protein (PrP) fragment, an integral component of the PrP region required for infectivity, is the major amyloid protein in Gerstmann-Sträussler-Scheinker disease A117V
F Tagliavini, P M Lievens, C Tranchant, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 26, 2023
Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort
Eric Jonasch, Todd M Bauer, Kyriakos P Papadopoulos, et al.
Nature Medicine
|
August 28, 2021
Author Correction: Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis
Toni K Choueiri, Todd M Bauer, Kyriakos P Papadopoulos, et al.
The Lancet. Oncology
|
April 14, 2025
Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study
Ramaprasad Srinivasan, Othon Iliopoulos, Kathryn E Beckermann, et al.
Nature Medicine
|
April 23, 2021
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis
Toni K Choueiri, Todd M Bauer, Kyriakos P Papadopoulos, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
January 23, 1996
Vascular variant of prion protein cerebral amyloidosis with tau-positive neurofibrillary tangles: the phenotype of the stop codon 145 mutation in PRNP
B Ghetti, P Piccardo, M G Spillantini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 23, 2024
Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study
Tobias Else, Eric Jonasch, Othon Iliopoulos, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
August 19, 2023
Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling
Dhananjay D Marathe, Petra M Jauslin, Huub Jan Kleijn, et al.
Page
of 16
Search research articles
Search
Showing results (111-120 of 159) with videos related to
Sort By:
Page
of 16
Journal of Clinical Pharmacology
|
May 16, 2024
Exposure-Response Analyses for Belzutifan to Inform Dosing Considerations and Labeling
Dhananjay D Marathe, Petra M Jauslin, Huub Jan Kleijn, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
January 21, 2017
Challenges and opportunities in primary CNS lymphoma: A systematic review
Mariana N Kerbauy, Fabio Y Moraes, Benjamin H Lok, et al.
The Journal of Biological Chemistry
|
November 23, 2000
A 7-kDa prion protein (PrP) fragment, an integral component of the PrP region required for infectivity, is the major amyloid protein in Gerstmann-Sträussler-Scheinker disease A117V
F Tagliavini, P M Lievens, C Tranchant, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 26, 2023
Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort
Eric Jonasch, Todd M Bauer, Kyriakos P Papadopoulos, et al.
Nature Medicine
|
August 28, 2021
Author Correction: Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis
Toni K Choueiri, Todd M Bauer, Kyriakos P Papadopoulos, et al.
The Lancet. Oncology
|
April 14, 2025
Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study
Ramaprasad Srinivasan, Othon Iliopoulos, Kathryn E Beckermann, et al.
Nature Medicine
|
April 23, 2021
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis
Toni K Choueiri, Todd M Bauer, Kyriakos P Papadopoulos, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
January 23, 1996
Vascular variant of prion protein cerebral amyloidosis with tau-positive neurofibrillary tangles: the phenotype of the stop codon 145 mutation in PRNP
B Ghetti, P Piccardo, M G Spillantini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 23, 2024
Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study
Tobias Else, Eric Jonasch, Othon Iliopoulos, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
August 19, 2023
Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling
Dhananjay D Marathe, Petra M Jauslin, Huub Jan Kleijn, et al.
Page
of 16